Evommune, Inc. (EVMN) News
Follow Evommune, Inc. (EVMN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Evommune Licenses Hinova Autoimmune Drug in Deal Worth Up to $1.1 Billion
Evommune said it licensed rights to an experimental autoimmune disease treatment from China's Hinova Pharmaceuticals, with up to about $1.1 billion in milestone payments.
MNA | Nov 04, 2026, 10:24 PM UTC
H
Evommune to Present Positive Phase 2a EVO301 Atopic Dermatitis Data as Late-Breaker at EADV 2026
Evommune announced a late-breaking oral presentation of positive Phase 2a data for EVO301 in moderate-to-severe atopic dermatitis at EADV 2026.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Sep. 23,
REGULATION | Sep 23, 2026, 08:15 PM UTC
L
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027—2028 milestones
Evommune posted an updated corporate presentation highlighting pipeline advances, ~$287M cash and runway into 2029.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Sep. 15, 2026This is an AI-powered su
REGULATION | Sep 15, 2026, 12:33 PM UTC
L
Evommune price target cut to $22 from $28
Leerink Partners cut its Evommune price target to $22.00 a share from $28.00, while maintaining an Outperform rating.
EQUITY | Sep 09, 2026, 04:03 PM UTC
L
RBC Capital cuts Evommune price target to $21 from $29
Benzinga, citing TradingView News, reports RBC Capital cut its Evommune price target to $21.00 per share from $29.00.
EQUITY | Sep 09, 2026, 01:43 PM UTC
M
Evommune shares plunge after eczema drug EVO756 fails mid-stage goals
Evommune (EVMN) shares fell more than 15% in extended trading after it said lead candidate EVO756 failed to meet main goals in a mid-stage eczema trial, citing topline data.
EQUITY | Sep 09, 2026, 10:51 AM UTC
M
Evommune says EVO756 phase 2b failed in atopic dermatitis
Evommune said EVO756 in moderate-to-severe atopic dermatitis did not meet primary or secondary endpoints and will be discontinued for AD.
REGULATION | Sep 09, 2026, 10:04 AM UTC
M
Evommune shares tumble 13% after-hours after eczema pill trial fails
Evommune (EVMN) shares fell 13% after-hours Tuesday after the company said its experimental eczema pill failed a mid-stage study and will not move forward in that disease.
EQUITY | Sep 08, 2026, 11:52 PM UTC
M
Evommune scraps eczema drug after mid-stage trial misses main goal
Evommune said it will not advance its experimental skin disease drug after failing to meet the main goal in a mid-stage trial, sending shares down 24% in aftermarket trading.
EQUITY | Sep 08, 2026, 10:17 PM UTC
L
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results
EQUITY | Sep 08, 2026, 10:10 PM UTC
H
EVMN Initiates Migraine Trial
EVMN starts phase 2b trial
EQUITY | Jul 30, 2026, 12:02 PM UTC
H
Top 3 Health Care Stocks That May Rocket Higher In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Jul 06, 2026, 10:11 AM UTC
L
Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE: EVMN ) with a Overweight and lowers the price target from $55 to $26.
EQUITY | Jun 30, 2026, 12:56 PM UTC
L
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst RJ
EQUITY | Jun 30, 2026, 12:51 PM UTC
H
Crude Oil Gains 2%; Comcast Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.44% to 52,105.66 while the NASDAQ rose 1.33% to 25,634.54. The S&P 500 also rose, gai
CENTRAL_BANK | Jun 29, 2026, 04:30 PM UTC